NEW YORK ( TheStreet) -- Shares of Sinovac Biotech (Nasdaq: SVA) have taken a tremendous swing upward. The stock is trading at $2.88 as of 10:15 a.m. ET, 22% above Monday's closing price of $2.36. Volume is at 308,720, 2.2 times the daily average of 140,300.

Sinovac Biotech has a market cap of $119.7 million and is part of the health care sector and drugs industry. Shares are down 47.8% year to date as of the close of trading on Monday.

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against the hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China.

TheStreet Ratings rates Sinovac Biotech as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and a generally disappointing performance in the stock itself. You can view the full Sinovac Biotech Ratings Report.

See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center.

Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
null

If you liked this article you might like

3 Biotech Stocks Under $10 in Breakout Territory

Sinopharm, Biostar, Lilly Rise on Medical Modernization in China

Sinovac Biotech Ltd. Stock Downgraded (SVA)

Sinovac Biotech Ltd. Stock Upgraded (SVA)

Rev Shark: An Odd Market Day